Literature DB >> 32632620

Reporting regression with melanoma in situ: reappraisal of a potential paradox.

Alexander M Cartron1, Paola C Aldana1, Amor Khachemoune2,3,4.   

Abstract

Melanoma in situ (MIS) is a form of radial growth phase melanoma in which the proliferation of malignant cells is confined to the epidermis. Histologic features are invaluable in recognition of MIS. Regression occurs when the host's immune system attacks the primary melanocytic tumor cells via tumor infiltrate lymphocytes, resulting in a fibrotic component. Various criteria have been proposed to assess the extent of histologic regression. Some authors define regression based on histologic features of the dermis, which is inappropriate for MIS. Specific dermatoscopic findings of regression in MIS have been reported including peppering, grey-blue areas, white areas, and blue-whitish veils. Many studies assess the impact of histologic regression on invasive melanoma prognosis, but no studies to-date have considered the effect of histologic regression exclusively in patients with MIS. The literature to-date does not suggest evaluation and management should be modified if histologic regression is present in MIS. Studies specifically investigating the effect of histologic regression on MIS prognosis are needed to inform evidence-based practices.

Entities:  

Keywords:  Dermatopathology; MIS; Melanoma in situ; Regression

Mesh:

Year:  2020        PMID: 32632620     DOI: 10.1007/s00403-020-02106-w

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Guidelines of care for the management of primary cutaneous melanoma.

Authors:  Susan M Swetter; Hensin Tsao; Christopher K Bichakjian; Clara Curiel-Lewandrowski; David E Elder; Jeffrey E Gershenwald; Valerie Guild; Jane M Grant-Kels; Allan C Halpern; Timothy M Johnson; Arthur J Sober; John A Thompson; Oliver J Wisco; Samantha Wyatt; Shasa Hu; Toyin Lamina
Journal:  J Am Acad Dermatol       Date:  2018-11-01       Impact factor: 11.527

Review 3.  Melanoma in situ: Part II. Histopathology, treatment, and clinical management.

Authors:  H William Higgins; Kachiu C Lee; Anjela Galan; David J Leffell
Journal:  J Am Acad Dermatol       Date:  2015-08       Impact factor: 11.527

4.  Skin biopsy rates and incidence of melanoma: population based ecological study.

Authors:  H Gilbert Welch; Steven Woloshin; Lisa M Schwartz
Journal:  BMJ       Date:  2005-08-04

5.  Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases.

Authors:  Joan Guitart; Lori Lowe; Michael Piepkorn; Victor G Prieto; Michael S Rabkin; Salve G Ronan; Christopher R Shea; Victor A Tron; Wain White; Raymond L Barnhill
Journal:  Arch Dermatol       Date:  2002-05

6.  Fully Regressive Melanoma: A Case Without Metastasis.

Authors:  Eric Ehrsam; Joseph R Kallini; Damien Lebas; Amor Khachemoune; Philippe Modiano; Hervé Cotten
Journal:  J Clin Aesthet Dermatol       Date:  2016-08-01

7.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

Review 8.  Emerging trends in the epidemiology of melanoma.

Authors:  V Nikolaou; A J Stratigos
Journal:  Br J Dermatol       Date:  2014-01       Impact factor: 9.302

9.  Clinical diagnosis and therapy of cutaneous melanoma in situ.

Authors:  C Bartoli; A Bono; C Clemente; I D Del Prato; S Zurrida; N Cascinelli
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

10.  Evaluation of MITF, SOX10, MART-1, and R21 Immunostaining for the Diagnosis of Residual Melanoma In Situ on Chronically Sun-Damaged Skin.

Authors:  Euphemia W Mu; Nicola A Quatrano; Sarah E Yagerman; Desiree Ratner; Shane A Meehan
Journal:  Dermatol Surg       Date:  2018-07       Impact factor: 3.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.